AKAleksei Dmitrievich Kravchenko

Aleksei Dmitrievich Kravchenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aleksei Dmitrievich Kravchenko has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Caco-2 Intestinal Permeability Study of Phenyltetrahydroquinolinedione Derivative – TRPA₁ Antagonist

    byΒ N. V. Pyatigorskaya, A. D. Kravchenko

    Introduction. This work is devoted to the intestinal permeability study of 7-(2-chlorophenyl)-4-(4-methyl-1,3-thiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione – innovative biologically active substance with TRPA1 antagonist activity. The phenyltetrahydroquinolinedione derivative is a promising analgesic and anti-inflammatory drug. To develop a dosage form of this new substance, it is necessary to study the mechanism and degree of its absorption.Aim. The aim of this work was to investigate the intestinal permeability of the phenyltetrahydroquinolinedione derivative using Caco-2 cell model and to compare experimental results with the in silico obtained values of the octanol/water partition coefficients.Materials and methods. The study of permeability was carried out from the apical membrane to the basolateral (A-B) and in the opposite direction (B-A). Ranitidine (low permeability), propranolol (high permeability) and rhodamine 123 (P-glycoprotein substrate) were used as control compounds. The concentration of the test compound was determined by UHPLC-MS/MS system consisting of a liquid chromatograph and a tandem mass spectrometer with a triple quadrupole and an electrospray ion source. The logP was calculated using the following resources: ChemDraw Professional 16.0, Molinspiration, ALOGPS 2.1.Results and discussion. The values of the apparent permeability (Papp) and efflux ratios of the test and control compounds were obtained. According to the results of the study, the following conclusions were made: the test compound has high permeability both in the forward direction from the apical to the basolateral cell membrane, and in the opposite direction (Papp > 10 Γ— 10-6 cm/s). P-glycoprotein-mediated efflux activity was not observed (the efflux ratio was less than 2 units). The permeability did not depend on the test compound input concentration. The obtained experimental Papp values were correlated with the in silico obtained values of partition coefficients. The best correlation was obtained for milogP (Molinspiration) and ClogP (ChemDraw).Conclusion. Thus, the in vitro and in silico obtained data indicate that passive diffusion is the main mechanism of absorption of the test compound in the gastrointestinal tract.


  • Open Access

    Transient receptor potential Ankyrin 1: structure, function and ligands

    byΒ Natalia V. Pyatigorskaya, Olga V. Filippova, Natalia S. Nikolenko, Aleksey D. Kravchenko

    Introduction: Transient receptor potential ankyrin 1 (TRPA1) is a protein expressed in many living organisms. During the study of TRPA1, its unique biological role as a universal and polymodal sensor of various altering agents was found. The aim of this study is to search and generalize information about structural features and molecular determinants, mechanisms of activation, action and modulation of TRPA1 as a universal pain and inflammation sensor, as well as the nature of activators and antagonists of this target and their therapeutic potential. Materials and methods: This article presents an overview of the results of scientific research of TRPA1, its modulators, as well as an overview of their pharmacological potential over the period from the discovery of these channels to the present, with an emphasis on the last decade. Results and discussion: The main collected data on expression, structural features and molecular determinants, mechaΒ­nisms of activation and action of TRPA1 indicate its role as a universal and labile element of the primary response of the body to adverse exogenous and endogenous factors. Regardless of the nature of the stimulus, hyperstimulation of TRPA1 channels can lead to such phenomena as pain, inflammation, itching, edema and other manifestations of alteration, and therefore TRPA1 blockade can be used in the treatment of various diseases accompanied by these pathological conditions. Currently, TRPA1 antagonists are being actively searched for and studied, as evidenced by a high patent activity over the past 14 years; however, the molecular mechanisms of action and pharmacological properties of TRPA1 blockers remain understudied. Conclusion: Acquire of new information about TRPA1 will help in the development of its modulators, which can beΒ­come promising analgesics, anti-inflammatory drugs, bronchodilators, and agents for the treatment of cardiovascular diseases of new generations.


  • Π˜Π·ΡƒΡ‡Π΅Π½ΠΈΠ΅ Ρ„ΠΈΠ·ΠΈΠΊΠΎ-химичСских свойств ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ Ρ„Π΅Π½ΠΈΠ»Ρ‚Π΅Ρ‚Ρ€Π°Π³ΠΈΠ΄Ρ€ΠΎΡ…ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° с TRPA1-антагонистичСской Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒΡŽ

    byΒ ΠΠ°Ρ‚Π°Π»ΡŒΡ Π’Π°Π»Π΅Ρ€ΡŒΠ΅Π²Π½Π° ΠŸΡΡ‚ΠΈΠ³ΠΎΡ€ΡΠΊΠ°Ρ, ΠΠ°Ρ‚Π°Π»ΡŒΡ Π‘Π΅Ρ€Π³Π΅Π΅Π²Π½Π° НиколСнко, АлСксСй Π”ΠΌΠΈΡ‚Ρ€ΠΈΠ΅Π²ΠΈΡ‡ ΠšΡ€Π°Π²Ρ‡Π΅Π½ΠΊΠΎ

    Показано, Ρ‡Ρ‚ΠΎ новая активная фармацСвтичСская субстанция с TRPA1-антагонистичСской Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒΡŽ (ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ΅ Ρ„Π΅Π½ΠΈΠ»Ρ‚Π΅Ρ‚Ρ€Π°Π³ΠΈΠ΄Ρ€ΠΎΡ…ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π°) прСдставляСт собой Π±Π΅Π»Ρ‹ΠΉ ΠΈΠ»ΠΈ ΠΏΠΎΡ‡Ρ‚ΠΈ Π±Π΅Π»Ρ‹ΠΉ мСлкокристалличСский нСгигроскопичный ΠΏΠΎΡ€ΠΎΡˆΠΎΠΊ, состоящий ΠΈΠ· частиц сфСричСской Ρ„ΠΎΡ€ΠΌΡ‹ с большой ΠΏΠ»ΠΎΡ‰Π°Π΄ΡŒΡŽ повСрхности: D90 ΠΈ span ΡΠΎΡΡ‚Π°Π²Π»ΡΡŽΡ‚ 22,2 ΠΌΠΊΠΌ ΠΈ 1,9 Π΅Π΄ΠΈΠ½ΠΈΡ† соотвСтствСнно. Бубстанция ΡƒΠΌΠ΅Ρ€Π΅Π½Π½ΠΎ растворима Π² этанолС 96 % ΠΈ практичСски нСрастворима Π² Π²ΠΎΠ΄Π΅ ΠΈ Π½-гСксанС, плавится Π² Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ Ρ‚Π΅ΠΌΠΏΠ΅Ρ€Π°Ρ‚ΡƒΡ€ ΠΎΡ‚ 203,5 Π΄ΠΎ 208,3 Β°C с Ρ€Π°Π·Π»ΠΎΠΆΠ΅Π½ΠΈΠ΅ΠΌ, тСряСт 0,11 % массы ΠΏΡ€ΠΈ Π²Ρ‹ΡΡƒΡˆΠΈΠ²Π°Π½ΠΈΠΈ, содСрТит 0,096 % Π²ΠΎΠ΄Ρ‹ ΠΈ 99,3 % Π΄Π΅ΠΉΡΡ‚Π²ΡƒΡŽΡ‰Π΅Π³ΠΎ вСщСства. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ Π΄Π°Π½Π½Ρ‹Π΅ ΠΎ Ρ„ΠΈΠ·ΠΈΠΊΠΎ-химичСских свойствах ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ Ρ„Π΅Π½ΠΈΠ»Ρ‚Π΅Ρ‚Ρ€Π°Π³ΠΈΠ΄Ρ€ΠΎΡ…ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° Π½Π°ΠΊΠ»Π°Π΄Ρ‹Π²Π°ΡŽΡ‚ ΠΎΠΏΡ€Π΅Π΄Π΅Π»Π΅Π½Π½Ρ‹Π΅ ограничСния Π½Π° Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΡƒ ΠΈ ΡƒΡΡ‚Π°Π½Π°Π²Π»ΠΈΠ²Π°ΡŽΡ‚ трСбования ΠΊ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Π°ΠΌ ΠΊ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½ΠΈΡŽ лСкарствСнных Ρ„ΠΎΡ€ΠΌ Π½Π° основС ΠΈΠ·ΡƒΡ‡Π°Π΅ΠΌΠΎΠ³ΠΎ вСщСства, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΌΠΎΠ³ΡƒΡ‚ Π±Ρ‹Ρ‚ΡŒ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Ρ‹ ΠΏΡ€ΠΈ обосновании ΠΏΡ€ΠΎΠ΅ΠΊΡ‚Π° спСцификации Π½Π° ΠΈΠ·ΡƒΡ‡Π°Π΅ΠΌΡƒΡŽ Π°ΠΊΡ‚ΠΈΠ²Π½ΡƒΡŽ Ρ„Π°Ρ€ΠΌΠ°Ρ†Π΅Π²Ρ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΡΡƒΠ±ΡΡ‚Π°Π½Ρ†ΠΈΡŽ.

  • Open Access

    Synthesis, molecular docking, ADMET study and in vitro pharmacological research of 7-(2-chlorophenyl)-4-(4-methylthiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione as a promising non-opioid analgesic drug

    byΒ Aleksey D. Kravchenko, Natalia V. Pyatigorskaya, Galina E. Brkich, Larysa V. Yevsieieva, Alexander V. Kyrychenko, Sergiy M. Kovalenko

    Introduction: The discovery of novel drugs that can block the transmission of pain signals for treating the pain of various etiologies is an urgent topic in pharmaceutics. The aim of this paper is to synthesize and to investigate in vitro and in silico characteristics of a promising novel compound: 7-(2-chlorophenyl)-4-(4-methylthiazol-5-yl)-4,6,7,8-tetrahydroquinoline-2,5(1H,3H)-dione (HSV-DKH-0450). Materials and methods: The specific activity and the inhibitory mechanism of HSV-DKH-0450 were studied using the HEK293 culture cells expressing the IPTG-induced TRPA1 ion channels. Cardiotoxicity was determined by estimating the binding of HSV-DKH-0450 to the hERG channel. Inhibition of human liver cytochromes was determined by the effect on the activity of cytochromes 1A2, 2C9, 2D6, 2C8, and 3A4. Cellular toxicity was assessed by the effect on the viability of human hepatocytes. ADMET properties were evaluated using admetSAR and SwissADME web-based tools. Molecular docking was carried out using AutoDock Vina tools to predict the binding affinity of all HSV-DKH-0450 stereoisomers toward the TRPA1 and TRPV1 receptors. Results and discussion: In silico predictions of ADMET properties of HSV-DKH-0450 showed that it has optimal pharmaceutical profiles. A series of in vitro pharmacological studies revealed that HSV-DKH-0450 is a promising antagonist of the TRPA1 ion channel with the IC50 of 91.3 nM. The molecular docking of HSV-DKH-0450 stereoisomers against the TRPA1 and TRPV1 receptors demonstrates that they all are characterized by an approximately similar high binding affinity. Conclusion: The obtained data for substance HSV-DKH-0450 look promising for its further development as a potential therapeutic agent for pain relief.


  • Polymorph screening and study of the structure of crystalline forms of phenyltetrahydroquinolinedione derivative with TRPA1-antagonistic activity

    byΒ Natalia Valeryevna Pyatigorskaya, Natalia Sergeevna Nikolenko, Aleksei Dmitrievich Kravchenko, Ekaterina Igorevna Nesterkina

    Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. 7-(2-Ρ…Π»ΠΎΡ€ΠΎΡ„Π΅Π½ΠΈΠ»)-4-(4-ΠΌΠ΅Ρ‚ΠΈΠ»-1,3-Ρ‚ΠΈΠ°Π·ΠΎΠ»-5-ΠΈΠ»)-4,6,7,8-Ρ‚Π΅Ρ‚Ρ€Π°Π³ΠΈΠ΄Ρ€ΠΎΡ…ΠΈΠ½ΠΎΠ»ΠΈΠ½-2,5(1Н,3Н)-Π΄ΠΈΠΎΠ½ являСтся Π½ΠΎΠ²Ρ‹ΠΌ сСлСктивным антагонистом Ρ€Π΅Ρ†Π΅ΠΏΡ‚ΠΎΡ€ΠΎΠ² TRPA1, ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΉ ΠΌΠΎΠΆΠ΅Ρ‚ ΡΡ‚Π°Ρ‚ΡŒ пСрспСктивным Π°Π½Π°Π»ΡŒΠ³Π΅Ρ‚ΠΈΡ‡Π΅ΡΠΊΠΈΠΌ ΠΈ ΠΏΡ€ΠΎΡ‚ΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ срСдством Π½ΠΎΠ²ΠΎΠ³ΠΎ поколСния. Для Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ Ρ‚Π²Π΅Ρ€Π΄ΠΎΠΉ лСкарствСнной Ρ„ΠΎΡ€ΠΌΡ‹ ΠΈΠ·ΡƒΡ‡Π°Π΅ΠΌΠΎΠ³ΠΎ вСщСства Π½Π΅ΠΎΠ±Ρ…ΠΎΠ΄ΠΈΠΌΠΎ ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ Π΅Π³ΠΎ характСристики, способныС Π²Π»ΠΈΡΡ‚ΡŒ Π½Π° критичСскиС ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ качСства Π³ΠΎΡ‚ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Π°. К Ρ‚Π°ΠΊΠΈΠΌ ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π°ΠΌ относится полиморфная модификация Π΄Π΅ΠΉΡΡ‚Π²ΡƒΡŽΡ‰Π΅Π³ΠΎ вСщСства. ЦСль исслСдования. ЦСлью Π΄Π°Π½Π½ΠΎΠΉ Ρ€Π°Π±ΠΎΡ‚Ρ‹ являлся ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Π½Ρ‹ΠΉ скрининг ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ Ρ„Π΅Π½ΠΈΠ»Ρ‚Π΅Ρ‚Ρ€Π°Π³ΠΈΠ΄Ρ€ΠΎΡ…ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° ΠΈ ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ строСния ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… кристалличСских ΠΌΠΎΠ΄ΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΉ с ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ Π΄ΠΈΡ„Ρ€Π°ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠ² Π°Π½Π°Π»ΠΈΠ·Π°. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠŸΠΎΡ€ΠΎΡˆΠΊΠΎΠ²Π°Ρ рСнтгСновская дифракция Π±Ρ‹Π»Π° ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° Π½Π° Π΄ΠΈΡ„Ρ€Π°ΠΊΡ‚ΠΎΠΌΠ΅Ρ‚Ρ€Π΅ Bruker D8 Discover, ΠΎΠ±ΠΎΡ€ΡƒΠ΄ΠΎΠ²Π°Π½Π½ΠΎΠΌ Π½ΠΈΠΊΠ΅Π»Π΅Π²Ρ‹ΠΌ Ρ„ΠΈΠ»ΡŒΡ‚Ρ€ΠΎΠΌ, Π° Ρ‚Π°ΠΊΠΆΠ΅ ΠΏΠΎΠ·ΠΈΡ†ΠΈΠΎΠ½Π½ΠΎ-Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ Π΄Π΅Ρ‚Π΅ΠΊΡ‚ΠΎΡ€ΠΎΠΌ. РасчСты ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Ρ‹ с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌΠ½Ρ‹Ρ… обСспСчСний DIFFRAC.SUITE EVA ΠΈ TOPAS 4.2. БъСмка ΠΎΡΡƒΡ‰Π΅ΡΡ‚Π²Π»ΡΠ»Π°ΡΡŒ Π² Π³Π΅ΠΎΠΌΠ΅Ρ‚Ρ€ΠΈΠΈ Брэгга-Π‘Ρ€Π΅Π½Ρ‚Π°Π½ΠΎ, Π² Ρ€Π΅ΠΆΠΈΠΌΠ΅ отраТСния. ΠœΠΎΠ½ΠΎΠΊΡ€ΠΈΡΡ‚Π°Π»Π»Ρ‹ ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Π½Ρ‹Ρ… ΠΌΠΎΠ΄ΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΉ Π±Ρ‹Π»ΠΈ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Ρ‹ ΠΏΡ€ΠΈ пСрСкристаллизации ΠΈΠ·ΡƒΡ‡Π°Π΅ΠΌΠΎΠ³ΠΎ вСщСства ΠΈΠ· Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… органичСских растворитСлСй ΠΈ ΠΈΡ… смСсСй. РСнтгСноструктурный Π°Π½Π°Π»ΠΈΠ· Π±Ρ‹Π» Π²Ρ‹ΠΏΠΎΠ»Π½Π΅Π½ Π½Π° ΠΌΠΎΠ½ΠΎΠΊΡ€ΠΈΡΡ‚Π°Π»ΡŒΠ½ΠΎΠΌ рСнтгСновском Π΄ΠΈΡ„Ρ€Π°ΠΊΡ‚ΠΎΠΌΠ΅Ρ‚Ρ€Π΅ Xcalibur-3. ΠœΠΎΠ½ΠΎΠΊΡ€ΠΈΡΡ‚Π°Π»ΡŒΠ½Ρ‹Π΅ структуры Ρ€Π°ΡΡˆΠΈΡ„Ρ€ΠΎΠ²Π°Π½Ρ‹ прямым ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ ΠΏΠΎ комплСксу ΠΏΡ€ΠΎΠ³Ρ€Π°ΠΌΠΌ SHELXTL. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ ΠΏΠΎΡ€ΠΎΡˆΠΊΠΎΠ²ΠΎΠΉ рСнтгСновской Π΄ΠΈΡ„Ρ€Π°ΠΊΡ†ΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡŒΠΊΠΈΡ… кристалличСских Ρ„Π°Π· Π² Π½Π°Ρ‚ΠΈΠ²Π½ΠΎΠΌ ΠΎΠ±Ρ€Π°Π·Ρ†Π΅ АЀБ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΎΠ½ΠΈ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΠΈΠ΄Π΅Π½Ρ‚ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ ΠΊΠΎΠ½ΠΊΡ€Π΅Ρ‚Π½Ρ‹Π΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Ρ‹. Π’ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Π½ΠΎΠ³ΠΎ скрининга ΠΈΠ· Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… растворитСлСй Π±Ρ‹Π»ΠΎ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½ΠΎ нСсколько монокристаллов, ΠΏΡ€ΠΈΠ³ΠΎΠ΄Π½Ρ‹Ρ… для рСнтгСноструктурного Π°Π½Π°Π»ΠΈΠ·Π°. ΠžΡ†Π΅Π½ΠΊΠ° ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… ΠΎΠ±Ρ€Π°Π·Ρ†ΠΎΠ² Π½Π΅ ΠΏΠΎΠΊΠ°Π·Π°Π»Π° Ρ€Π°Π·Π»ΠΈΡ‡ΠΈΠΉ Π² растворимости ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„ΠΎΠ². Π‘Ρ‹Π»ΠΎ установлСно, Ρ‡Ρ‚ΠΎ ΠΈΠ· этанола кристаллизуСтся ромбичСская модификация I, Π° ΠΈΠ· ΠΌΠ΅Ρ‚Π°Π½ΠΎΠ»Π°, ΠΈΠ·ΠΎΠΏΡ€ΠΎΠΏΠ°Π½ΠΎΠ»Π°, Π°Ρ†Π΅Ρ‚ΠΎΠ½Π°, смСсСй Π°Ρ†Π΅Ρ‚ΠΎΠ½/Π°Ρ†Π΅Ρ‚ΠΎΠ½ΠΈΡ‚Ρ€ΠΈΠ» ΠΈΠ»ΠΈ Π’Π“Π€/Π°Ρ†Π΅Ρ‚ΠΎΠ½ΠΈΡ‚Ρ€ΠΈΠ» - триклинная модификация II. Π‘Ρ‹Π»ΠΈ описаны различия Π² молСкулярном строСнии ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„ΠΎΠ² ΠΈ ΠΈΡ… ΡƒΠΏΠ°ΠΊΠΎΠ²ΠΊΠΈ Π² кристаллах. Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. ΠŸΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ ΠΈ ΠΎΡ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΠΎΠ²Π°Π½Π½Ρ‹Π΅ ΠΏΠΎΠ»ΠΈΠΌΠΎΡ€Ρ„Ρ‹ АЀБ ΠΌΠΎΠ³ΡƒΡ‚ Π±Ρ‹Ρ‚ΡŒ ΠΎΡ†Π΅Π½Π΅Π½Ρ‹ с Ρ†Π΅Π»ΡŒΡŽ Π²Ρ‹Π±ΠΎΡ€Π° ΠΊΠΎΠ½ΠΊΡ€Π΅Ρ‚Π½ΠΎΠΉ кристалличСской ΠΌΠΎΠ΄ΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΈ для дальнСйшСй Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ Ρ‚Π²Π΅Ρ€Π΄ΠΎΠΉ лСкарствСнной Ρ„ΠΎΡ€ΠΌΡ‹ Π½Π° Π΅Π΅...

  • The study of technological properties and biopharmaceutical solubility of phenyltetrahydroquinolinedione derivative with TRPA1-antagonistic activity

    byΒ Natal'YA Valer'EVna Pyatigorskaya, Natal'YA Sergeevna Nikolenko, Aleksei Dmitrievich Kravchenko

    Π’Π²Π΅Π΄Π΅Π½ΠΈΠ΅. Π’ соотвСтствии с ΠΏΡ€ΠΈΠ½Ρ†ΠΈΠΏΠ°ΠΌΠΈ, Π·Π°Π»ΠΎΠΆΠ΅Π½Π½Ρ‹ΠΌΠΈ Π² руководствС ICH Q8, для посСрийного производства лСкарствСнного ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Π° Π΄ΠΎΠ»ΠΆΠ½Ρ‹ Π±Ρ‹Ρ‚ΡŒ ΠΈΠ·ΡƒΡ‡Π΅Π½Ρ‹ критичСскиС ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Ρ‹ Π΅Π³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ‚ΠΎΠ², способныС Π²Π»ΠΈΡΡ‚ΡŒ Π½Π° качСство Π³ΠΎΡ‚ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ‚Π°. К ΠΏΠΎΠ΄ΠΎΠ±Π½Ρ‹ΠΌ ΠΏΠ°Ρ€Π°ΠΌΠ΅Ρ‚Ρ€Π°ΠΌ относятся тСхнологичСскиС ΠΈ биофармацСвтичСскиС свойства Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΠΉ фармацСвтичСской субстанции. ЦСль Ρ€Π°Π±ΠΎΡ‚Ρ‹: ΠΈΠ·ΡƒΡ‡Π΅Π½ΠΈΠ΅ тСхнологичСских свойств ΠΈ биофармацСвтичСской растворимости ΠΏΡ€ΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ Ρ„Π΅Π½ΠΈΠ»Ρ‚Π΅Ρ‚Ρ€Π°Π³ΠΈΠ΄Ρ€ΠΎΡ…ΠΈΠ½ΠΎΠ»ΠΈΠ½Π΄ΠΈΠΎΠ½Π° - антагониста TRPA1 для Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠΈ Ρ‚Π²Π΅Ρ€Π΄ΠΎΠΉ лСкарствСнной Ρ„ΠΎΡ€ΠΌΡ‹ (Π›Π€) Π½Π° Π΅Π³ΠΎ основС. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Π‘Ρ‹ΠΏΡƒΡ‡Π΅ΡΡ‚ΡŒ ΠΈ ΡƒΠ³ΠΎΠ» СстСствСнного откоса опрСдСляли с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ тСстСра сыпучСсти Erweka GTL. Насыпной объСм Π΄ΠΎ ΠΈ послС уплотнСния устанавливали с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ тСстСра насыпной плотности ETD-1020. Π Π°Π²Π½ΠΎΠ²Π΅ΡΠ½ΡƒΡŽ Π±ΠΈΠΎ-Ρ„Π°Ρ€ΠΌΠ°Ρ†Π΅Π²Ρ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ Ρ€Π°ΡΡ‚Π²ΠΎΡ€ΠΈΠΌΠΎΡΡ‚ΡŒ опрСдСляли Π½Π° тСстСрС для провСдСния испытания «РастворСниС» DT 626/1000 HH. ΠšΠΎΠ»ΠΈΡ‡Π΅ΡΡ‚Π²ΠΎ ΠΏΠ΅Ρ€Π΅ΡˆΠ΅Π΄ΡˆΠ΅Π³ΠΎ Π² раствор вСщСства опрСдСляли Π½Π° Π£Π€-спСктрофотомСтрС Agilent 8453. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π‘Ρ‹ΠΏΡƒΡ‡Π΅ΡΡ‚ΡŒ для Π²ΠΎΡ€ΠΎΠ½ΠΊΠΈ Π΄ΠΈΠ°ΠΌΠ΅Ρ‚Ρ€ΠΎΠΌ 25 ΠΌΠΌ составила 18,68Β±1,15 Π³/с, ΡΠΎΠΎΡ‚Π²Π΅Ρ‚ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΠΉ ΡƒΠ³ΠΎΠ» СстСствСнного откоса - 46,37Β±2,04Β°, коэффициСнт прСссуСмости ΠΈ Π₯ауснСра - 31,83Β±1,33%, ΠΈ 1,47Β±0,09 Π•Π΄ соотвСтствСнно. Ни ΠΏΡ€ΠΈ ΠΎΠ΄Π½ΠΎΠΌ Π·Π½Π°Ρ‡Π΅Π½ΠΈΠΈ pH рассчитанная тСрапСвтичСская Π΄ΠΎΠ·Π° вСщСства Π½Π΅ Ρ€Π°ΡΡ‚Π²ΠΎΡ€ΡΠ»Π°ΡΡŒ ΠΏΠΎΠ»Π½ΠΎΡΡ‚ΡŒΡŽ Π² 250 ΠΌΠ» срСды. БиофармацСвтичСскиС растворимости ΠΏΡ€ΠΈ pH 1,2, 4,5 ΠΈ 6,8 составили 26,64Β±1,36; 2,72Β±0,15 ΠΈ 3,8Β±0,21 ΠΌΠΊΠ³/ΠΌΠ» соотвСтствСнно. Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π”Π°Π½Π½Ρ‹Π΅ ΠΎ тСхнологичСских свойствах ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚ ΡΠ΄Π΅Π»Π°Ρ‚ΡŒ Π²Ρ‹Π²ΠΎΠ΄ ΠΎ нСобходимости примСнСния ΠΌΠ΅Ρ‚ΠΎΠ΄Π° грануляции ΠΈΠ»ΠΈ использования Π²ΡΠΏΠΎΠΌΠΎΠ³Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… вСщСств для прямого прСссования, Π° ΠΏΡ€ΠΎΡ„ΠΈΠ»ΡŒ растворСния ΠΈΠ·ΡƒΡ‡Π°Π΅ΠΌΠΎΠ³ΠΎ вСщСства ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡŽΡ‚ отнСсти Π΅Π³ΠΎ ΠΊΠΎ II ΠΈΠ»ΠΈ IV классу биофармацСвтичСской классификационной систСмы, Π² связи с Ρ‡Π΅ΠΌ Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚ΠΊΠ° Π›Π€ Π΄ΠΎΠ»ΠΆΠ½Π° Π±Ρ‹Ρ‚ΡŒ Π½Π°ΠΏΡ€Π°Π²Π»Π΅Π½Π° Π½Π° ΡƒΠ²Π΅Π»ΠΈΡ‡Π΅Π½ΠΈΠ΅ растворимости ΠΈΠ»ΠΈ растворимости ΠΈ проницаСмости...